Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
(St. Jude Reference #)
|Treatment of Ocular Cancers with p53 Activators
|Description||Treatment of ocular cancers, such as retinoblastoma, using activators of the p53 pathway is provided. Compounds which inhibit the effect of MDM2 and MDMX on p53, such as nutlin-3, are identified as useful for activating p53 and treating ocular cancers.|
|Keywords||MDMX, MDM2, p53, retinoblastoma, nutlin|
|Granted Patents or Published Applications||Pending U.S. Patent Appln.published Dec. 3, 2009 as Pub. No. 2009/0298785|
|Related Scientific References||Laurie, N.A. et al., “Targeting MDM2 and MDMX in retinoblastoma”, Curr. Cancer Drug Targets 7(7): 689-695 (2007); Marine, J.C. et al., “MDMX: from bench to bedside”, J. Cell Science 120(Pt3): 371-378 (2007); Laurie, N.A. et al., “Inactivation of the p53 pathway in retinoblastoma”, Nature 444(7115): 61-66 (2006).|
|Licensing Opportunities||We are currently seeking licensing opportunities in all fields for the development of this technology.|
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.
Last update: September 2010